Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.

Novo Nordisk

Pharmaceutical

Denmark

The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The pharmaceutical industry is developing at an unusually rapid pace. The market for pharmaceuticals is growing persistently, and expenses for drugs will amount to $1.5 trillion globally by 2021. Together with Canada and Mexico, it represents the largest continental pharma market worldwide. Investments in biopharmaceutical innovation are driving contributions to the American economy and solidifying America’s role as a leader in medical innovation. The pharmaceuticals sector is forecasted to grow faster than any other market in the next five years with an emphasis on R&D.

Irvine

United States of America

California

10,001+ Employees

Are you new for initiating your diabetes treatment on a disposable pen? This video provides a step-by-step guide on steps while ...

Careers and Openings at Novo Nordisk